The approval of gepotidacin (Blujepa; GSK) introduces the first new class of oral antibiotics for uncomplicated urinary tract ...

This antibiotic is the first new FDA-approved medication for urinary tract infections in decades, and meets the need for new ...

The U.S. Food and Drug Administration has granted approval to a new antibiotic to treat urinary tract infections in women and ...

The Food and Drug Administration has approved a new antibiotic that can treat uncomplicated urinary tract infections, or ...

GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of ...

Gepotidacin is an oral, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by blocking 2 different type II topoisomerase enzymes.

Blujepa, which is made by the British pharmaceutical company GSK plc, is approved for the treatment of women and children ...

In EAGLE-3, statistically significant superiority was demonstrated for Blujepa versus nitrofurantoin ... the first in a new ...

The FDA approved gepotidacin for the treatment of uncomplicated UTIs in women and adolescent girls aged 12 years or older, ...

Blujepa is part of a new class of antibiotics called triazaacenaphthylenes ... compared to 43% to 47% in a group that received the antibiotic nitrofurantoin. More than half of women will ...